Coacervate-mediated novel pancreatic cancer drug Aleuria Aurantia lectin delivery for augmented anticancer therapy
Tóm tắt
Pancreatic cancer, one of the cancers with the highest mortality rate, has very limited clinical treatment. Cancer cells express abnormal glycans on the surface, and some lectins with a high affinity for the glycans induce apoptosis in cancer. In this study, the efficacy of Aleuria Aurantia lectin (AAL) for the treatment of pancreatic cancer was evaluated and the efficacy improvement through AAL delivery with mPEGylated coacervate (mPEG-Coa) was investigated. AAL was treated with pancreatic cancer cells, PANC-1, and the expression level of caspase-3 and subsequent apoptosis was analyzed. In particular, the anticancer efficacy of AAL was compared with that of concanavalin A, one of the representative anticancer lectins. Then, methoxypolyethylene glycol-poly(ethylene arginylaspartate diglyceride), a polycation, was synthesized, and an mPEG-Coa complex was prepared with polyanion heparin. The AAL was incorporated into the mPEG-Coa and the release kinetics of the AAL from the mPEG-Coa and the cargo protection capacity of the mPEG-Coa were evaluated. Finally, improved anticancer ability through Coa-mediated AAL delivery was assessed. These results indicated that AAL is a potential effective pancreatic cancer treatment. Moreover, mPEG-Coa rapidly released AAL at pH 6.5, an acidic condition in the cancer microenvironment. The initial rapid release of AAL effectively suppressed pancreatic cancer cells, and the continuous supply of AAL through the Coa transporter effectively inhibited proliferation recurrence of cancer cells. AAL is a potential novel drug for the treatment of pancreatic cancer therapeutic agent. In addition, a continuous supply of drugs above the therapeutic threshold using mPEG-Coa could improve therapeutic efficacy.
Tài liệu tham khảo
Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96(8):1183–90.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Gu Z, Du Y, Zhao X, Wang C. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. Cancer Lett. 2021;521:98–108.
Paroha S, Verma J, Dubey RD, Dewangan RP, Molugulu N, Bapat RA, et al. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm. 2021;592:120043.
Mazalovska M, Kouokam JC. Plant-derived lectins as potential cancer therapeutics and diagnostic tools. Biomed Res Int. 2020;1631394.
Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis. 2008;13(1):1–9.
Gondim ACS, Romero-Canelon I, Sousa EHS, Blindauer CA, Butler JS, Romero MJ, et al. The potent anti-cancer activity of Dioclea lasiocarpa lectin. J Inorg Biochem. 2017;175:179–89.
Choi Y, Kim J, Chae J, Hong J, Park J, Jeong E, et al. Surface glycan targeting for cancer nano-immunotherapy. J Control Release. 2022;342:321–36.
Hung LD, Trinh PTH. Structure and anticancer activity of a new lectin from the cultivated red alga, Kappaphycus striatus. J Nat Med. 2021;75(1):223–31.
Jiang QL, Zhang S, Tian M, Zhang SY, Xie T, Chen DY, et al. Plant lectins, from ancient sugar-binding proteins to emerging anti-cancer drugs in apoptosis and autophagy. Cell Prolif. 2015;48(1):17–28.
Yau T, Dan XL, Ng CCW, Ng TB. Lectins with potential for anti-cancer therapy. Molecules. 2015;20(3):3791–810.
Choi Y, Park U, Koo HJ, Park JS, Lee DH, Kim K, et al. Exosome-mediated diagnosis of pancreatic cancer using lectin-conjugated nanoparticles bound to selective glycans. Biosens Bioelectron. 2021;112980.
Postupalenko V, Desplancq D, Orlov I, Arntz Y, Spehner D, Mely Y, et al. Protein delivery system containing a nickel-immobilized polymer for multimerization of affinity-purified his-tagged proteins enhances cytosolic transfer. Angew Chem-Int Ed. 2015;54(36):10583–6.
Jo H, Gajendiran M, Kim K. Development of polymer coacersome structure with enhanced colloidal stability for therapeutic protein delivery. Macromol Biosci. 2019;19(12):1900207.
Jo H, Gajendiran M, Kim K. Influence of PEG chain length on colloidal stability of mPEGylated polycation based coacersomes for therapeutic protein delivery. J Ind Eng Chem. 2020;82:234–42.
Kim S, Kim J, Gajendiran M, Yoon M, Hwang MP, Wang YD, et al. Enhanced skull bone regeneration by sustained release of BMP-2 in interpenetrating composite hydrogels. Biomacromolecules. 2018;19(11):4239–49.
Kim S, Lee J, Hwang MP, Wang YD, Kim K. Influence of fiber architecture and growth factor formulation on osteoblastic differentiation of mesenchymal stem cells in coacervate-coated electrospun fibrous scaffolds. J Ind Eng Chem. 2019;79:236–44.
Cho H, Kim J, Kim S, Jung YC, Wang Y, Kang BJ, et al. Dual delivery of stem cells and insulin-like growth factor-1 in coacervate-embedded composite hydrogels for enhanced cartilage regeneration in osteochondral defects. J Control Release. 2020;327:284–95.
Park U, Lee MS, Jeon J, Lee S, Hwang MP, Wang Y, et al. Coacervate-mediated exogenous growth factor delivery for scarless skin regeneration. Acta Biomater. 2019;90:179–91.
Lee MS, Ahmad T, Lee J, Awada HK, Wang YD, Kim K, et al. Dual delivery of growth factors with coacervate-coated poly(lactic-co-glycolic acid) nanofiber improves neovascularization in a mouse skin flap model. Biomaterials. 2017;124:65–77.
Fu LL, Zhou CC, Yao S, Yu JY, Liu B, Bao JK. Plant lectins: targeting programmed cell death pathways as antitumor agents. Int J Biochem Cell Biol. 2011;43(10):1442–9.
Bhutia SK, Panda PK, Sinha N, Praharaj PP, Bhol CS, Panigrahi DP, et al. Plant lectins in cancer therapeutics: targeting apoptosis and autophagy-dependent cell death. Pharmacol Res. 2019;144:8–18.
Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res. 1999;59(9):2083–90.
Lyu SY, Choi SH, Park WB. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharm Res. 2002;25(1):93–101.
Choi SH, Lyu SY, Park WB. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res. 2004;27(1):68–76.
Nascimento APM, Knaut JL, Rieger DK, Wolin IAV, Heinrich IA, Mann J, et al. Anti-glioma properties of DVL, a lectin purified from Dioclea violacea. Int J Biol Macromol. 2018;120:566–77.
Yang Y, Xu HL, Zhang ZT, Liu JJ, Li WW, Ming H, et al. Characterization, molecular cloning, and in silico analysis of a novel mannose-binding lectin from Polygonatum odoratum (Mill.) with anti-HSV-II and apoptosis-inducing activities. Phytomedicine. 2011;18(8–9):748–55.
Lei HY, Chang CP. Lectin of Concanavalin a as an anti-hepatoma therapeutic agent. J Biomed Sci. 2009;10.
Shi Z, Chen J, Li CY, An N, Wang ZJ, Yang SL, et al. Antitumor effects of concanavalin a and Sophora flavescens lectin in vitro and in vivo. Acta Pharmacol Sin. 2014;35(2):248–56.
Liu B, Li CY, Bian HJ, Min MW, Chen LF, Bao JK. Antiproliferative activity and apoptosis-inducing mechanism of Concanavalin A on human melanoma A375 cells. Arch Biochem Biophys. 2009;482(1–2):1–6.
Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6(2):99–104.
Yadav P, Yadav R, Jain S, Vaidya A. Caspase-3: a primary target for natural and synthetic compounds for cancer therapy. Chem Biol Drug Des. 2021;98(1):144–65.
Koshkina O, Raju LT, Kaltbeitzel A, Riedinger A, Lohse D, Zhang X, et al. Surface properties of colloidal particles affect colloidal self-assembly in evaporating self-lubricating ternary droplets. ACS Appl Mater Interfaces. 2022;14(1):2275–90.
Last MGF, Deshpande S, Dekker C. pH-controlled Coacervate-membrane interactions within liposomes. ACS Nano. 2020;14(4):4487–98.
Gajendiran M, Kim S, Jo H, Kim K. Fabrication of pH responsive coacervates using a polycation-b-polypropylene glycol diblock copolymer for versatile delivery platforms. J Ind Eng Chem. 2020;90:36–46.
Kim K, Chen WCW, Heo Y, Wang YD. Polycations and their biomedical applications. Prog Polym Sci. 2016;60:18–50.
Chu H, Gao J, Chen CW, Huard J, Wang Y. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis. Proc Natl Acad Sci U S A. 2011;108(33):13444–9.
Hwang MP, Fecek RJ, Qin T, Storkus WJ, Wang Y. Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. J Control Release. 2020;318:270–8.
Feng LZ, Dong ZL, Tao DL, Zhang YC, Liu Z. The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev. 2018;5(2):269–86.
Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Del Rev. 2006;58(14):1523–31.
Monnery BD, Wright M, Cavill R, Hoogenboom R, Shaunak S, Steinke JHG, et al. Cytotoxicity of polycations: relationship of molecular weight and the hydrolytic theory of the mechanism of toxicity. Int J Pharm. 2017;521(1–2):249–58.
Wytrwal-Sarna M, Knobloch P, Michalik M, Nowakowska M, Kepczynski M. Effect of polycation nanostructures on cell membrane permeability and toxicity. Environ Sci-Nano. 2022;9(2):702–13.
Jayanthi S, Koppolu BP, Nguyen KG, Smith SG, Felber BK, Kumar TKS, et al. Modulation of Interleukin-12 activity in the presence of heparin. Sci Rep. 2017;7(1):5360.